Top

Published in:

01-02-2013 | Review Article

Leflunomide: friend or foe for systemic lupus erythematosus?

Authors: Guo-Cui Wu, Xiao-Di Xu, Qiong Huang, Hua Wu

Published in: Rheumatology International | Issue 2/2013

Abstract

Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.

Smolen JS, Graninger WB, Emery P (2000) Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford) 39:689–692CrossRef

Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550PubMedCrossRef

Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266PubMedCrossRef

Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665PubMedCrossRef

Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59:841–849PubMedCrossRef

Popovic S, Bartlett RR (1987) The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 21:284–286PubMedCrossRef

Bartlett RR, Popovic S, Raiss RX (1988) Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 75:290–299PubMedCrossRef

Petera P, Manger B, Rosenburg R et al (2000) A pilot study of leflunomide in systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241

Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483PubMedCrossRef

10.

Petri M (2001) High dose arava in lupus (HAIL). Arthritis Rheum 44:S280

11.

Kessel A, Toubi E (2002) Leflunomide in systemic lupus erythematosus. Harefuah 141:355–357PubMed

12.

Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13:601–604PubMedCrossRef

13.

Cui TG, Hou FF, Ni ZH et al (2005) Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi 44:672–676 [In Chinese]PubMed

14.

Tam LS, Li EK, Wong CK et al (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65:417–418PubMedCrossRef

15.

Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17:638–644PubMedCrossRef

16.

Holm EA, Balslev E, Jemec GB (2001) Vasculitis occurring during leflunomide therapy. Dermatology 203:258–259PubMedCrossRef

17.

Carulli MT, Davies UM (2002) Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology 41:952–953PubMedCrossRef

18.

Soliotis F, Glover M, Jawad AS (2002) Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 61:850–851PubMedCrossRef

19.

Chan AT, Bradlow A, McNally J (2003) Leflunomide induced vasculitisea dose-response relationship. Rheumatology 42:492–493PubMedCrossRef

20.

Fischer TW, Bauer HI, Graefe T et al (2003) Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 207:386–389PubMedCrossRef

21.

van Roon EN, Jansen TL et al (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27:345–352PubMedCrossRef

22.

Chan J, Sanders DC, Du L et al (2004) Leflunomide associated pancytopenia with or without methotrexate. Ann Pharmacother 38:1206–1211PubMedCrossRef

23.

Bharadwaj A, Haroon N (2004) Peripheral neuropathy in patients on leflunomide. Rheumatology 43:934PubMedCrossRef

24.

Bonnel RA, Graham DJ (2004) Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 75:580–585PubMedCrossRef

25.

Kamata Y, Nara H, Kamimura T et al (2004) Rheumatoid arthritis complicated with acute intersitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201–1204PubMedCrossRef

26.

Kerr OA, Murray CS, Tidman MJ (2004) Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 29:319–320PubMedCrossRef

27.

Goeb V, Berhelot JM, Joly P et al (2005) Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology 44:823–824PubMedCrossRef

28.

Gensburger D, Kawashima M, Marotte H et al (2005) Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 64:153–155PubMedCrossRef

29.

Takeishi M, Akiyama Y, Akiba H et al (2005) Leflunomide induced acute interstitial pneumonia. J Rheumatol 32:1160–1163PubMed

30.

Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208PubMedCrossRef

31.

González-Alvaro I, Ortiz AM, Domínguez-Jiménez C et al (2009) Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 68:1644–1650PubMedCrossRef

32.

Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962–5969PubMed

33.

Manna SK, Aggarwal BB (1999) Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162:2095–2102PubMed

34.

He C, Lu X, Yan Z et al (2012) Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int 32:633–638PubMedCrossRef

35.

Bes C, Soy M (2011) Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. Rheumatol Int 31:521–523PubMedCrossRef

36.

Suess A, Sticherling M (2008) Leflunomide in subacute cutaneous lupus erythematosus-two sides of a coin. Int J Dermatol 47:83–86PubMedCrossRef

37.

Chan SK, Hazleman BL, Burrows NP (2004) Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 29:724–725

Title: Leflunomide: friend or foe for systemic lupus erythematosus?
Authors: Guo-Cui Wu
Xiao-Di Xu
Qiong Huang
Hua Wu
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 2/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-012-2508-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Leflunomide: friend or foe for systemic lupus erythematosus?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Preliminary report on a study of health-related quality of life in patients with rheumatoid arthritis

Rapid infusion with rituximab: short term safety in systemic autoimmune diseases

Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA

IRAK1 rs3027898 C/A polymorphism is associated with risk of rheumatoid arthritis

Effects of short-term aerobic exercise with and without external loading on bone metabolism and balance in postmenopausal women with osteoporosis

Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page